CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.7200
-0.0100 (-1.37%)
Apr 1, 2025, 4:00 PM EDT - Market closed

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.562.892.840.43
Other Operating Expenses
0.040.040.060.14
Operating Expenses
10.482.932.910.57
Operating Income
-10.48-2.93-2.91-0.57
Interest & Investment Income
0.380.492.84-
EBT Excluding Unusual Items
-5.39-2.44-0.07-0.57
Gain (Loss) on Sale of Investments
----0
Pretax Income
-5.39-2.44-0.07-0.57
Income Tax Expense
0.090.090.6-0.03
Net Income
-5.49-2.54-0.67-0.54
Preferred Dividends & Other Adjustments
---36.16
Net Income to Common
-5.49-2.54-0.67-36.71
Shares Outstanding (Basic)
0000
Shares Outstanding (Diluted)
0000
Shares Change (YoY)
63.59%-70.97%133.12%-
EPS (Basic)
-27.84-38.85-2.97-
EPS (Diluted)
-27.84-38.85-2.97-
EBIT
-10.48-2.93-2.91-0.57
Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q